Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.